Last reviewed · How we verify
iNO
iNO is inhaled nitric oxide gas that dilates pulmonary blood vessels and improves oxygenation in patients with severe respiratory failure.
iNO is inhaled nitric oxide gas that dilates pulmonary blood vessels and improves oxygenation in patients with severe respiratory failure. Used for Acute respiratory distress syndrome (ARDS), Persistent pulmonary hypertension of the newborn (PPHN), Hypoxic respiratory failure.
At a glance
| Generic name | iNO |
|---|---|
| Also known as | Inhaled Nitrous Oxide, Inhaled Nitric Oxide, Inhaled nitric oxide. |
| Sponsor | Wake Forest University Health Sciences |
| Drug class | Inhaled vasodilator |
| Target | Soluble guanylate cyclase |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Respiratory |
| Phase | FDA-approved |
Mechanism of action
Nitric oxide is a potent selective pulmonary vasodilator that reduces pulmonary vascular resistance and improves ventilation-perfusion matching in the lungs. By preferentially dilating vessels in well-ventilated lung regions, iNO enhances oxygen uptake and reduces intrapulmonary shunting, thereby improving arterial oxygenation in critically ill patients.
Approved indications
- Acute respiratory distress syndrome (ARDS)
- Persistent pulmonary hypertension of the newborn (PPHN)
- Hypoxic respiratory failure
Common side effects
- Methemoglobinemia
- Nitrogen dioxide formation
- Rebound hypoxemia upon discontinuation
Key clinical trials
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL (PHASE2)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL (PHASE2)
- Effect of iNO in Patients With Submassive and Massive PE (PHASE2)
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (PHASE3)
- Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iNO CI brief — competitive landscape report
- iNO updates RSS · CI watch RSS
- Wake Forest University Health Sciences portfolio CI